| abstract |
The present invention relates to pharmaceutical formulations containing scopolamine. More particularly, the invention relates to an intranasal gel formulation including scopolamine hydrobromide in a pharmaceutically acceptable carrier, most preferably an intranasal gel, at a pH at or below about 4.0, preferably at or below about 3.5, and a salt concentration below about 200 mM, with the gel solution incorporating polyvinylalcohol as a gelling agent. The intranasal formulations are particularly useful for preventing and/or treating nausea and/or vomiting associated with, for example, motion sickness. |